Inferra AIResearch Tools

Inferra AI / Company / CNMD

CONMED Corp

CNMD · Health Care

Last earnings Oct 28, 2026

Key results

Domestic revenuequarter

5.9%

Domestic revenue increased 5.9% year-over-year.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

International revenuequarter

7.8%

International revenue increased 7.8% year-over-year as reported and 6.8% in constant currency.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

EPSquarter

$0.09

Diluted net earnings per share (GAAP) were $0.09, compared to diluted net earnings per share (GAAP) of $1.57 in the third quarter of 2024.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Adjusted diluted net earnings per share (1) were $1.08, compared to adjusted diluted net earnings per share of $1.05 in the third quarter of 2024.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

AI analysis

Q3 2025 · reported Nov 5, 2025

Based on: Earnings release + parent 8-K — transcript not held

EPS · Q3 2025
$0.09
EX-99 · Nov 5, 2025

Headline figures

MetricQ3 2025Prior qtrYear ago
Domestic revenue5.9%——
International revenue7.8%——
EPS$0.09——

EX-99 · Nov 5, 2025

Guidance · company-stated

No guidance located in the held release

Stated figure6.7%
Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Dividend$25.0M

Subsequent to quarter end, the Board of Directors authorized a $150.0 million share repurchase program and suspended the quarterly cash dividend the Company anticipates repurchasing at least $25.0 million in shares annually beginning in 2026.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

CONTACT CONMED Corporation Todd W

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

Subsequent to quarter end, the Board of Directors authorized a $150.0 million share repurchase program and suspended the quarterly cash dividend the Company anticipates repurchasing at least $25.0 million in shares annually beginning in 2026.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Share Repurchase Authorization and Suspension of Dividend Payments Effective October 31, 2025, CONMED s Board of Directors authorized a $150.0 million share repurchase program (the Modified Program ), which modified its prior $200.0 million share repurchase program (the Prior Program ), under which $37.4 million had remained available for repurchases prior to the establishment of the Modified Program.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

With the decision to extend the share repurchase program, the Board of Directors suspended the Company s quarterly cash dividend.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

The Company expects to repurchase at least $25.0 million in shares annually beginning in 2026.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Risks & headwinds

2025 Outlook Based on current foreign currency exchange rates, the Company continues to expect revenue currency headwinds to be immaterial.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

The Company now expects full-year adjusted diluted net earnings per share (2) in the range of $4.48 to $4.53, with foreign currency estimated to be a headwind of approximately 10 cents.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

This is compared to its prior range of $4.40 to $4.55, with foreign currency then estimated to be a headwind of approximately 10 cents.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

This updated guidance includes the effects of recent tariff announcements, which the Company estimates would result in a negative impact to EPS of approximately $0.07 in the fourth quarter of 2025.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Forward-Looking Statements This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC.

SEC original ↗CONMED Corp — Earnings release (8-K exhibit)EX-99Nov 5, 2025

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

30 documents

Earnings releases

46 documents

Presentations

0 documents

No presentations for CONMED Corp are held in this edition of the library.

Transcripts

0 documents

No transcripts for CONMED Corp are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.